Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
April 26, 2024 19:03 ET
|
Appili Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
April 02, 2024 07:30 ET
|
Appili Therapeutics Inc.
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR...
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
March 12, 2024 07:12 ET
|
Appili Therapeutics Inc.
HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for...
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
February 13, 2024 17:49 ET
|
Appili Therapeutics Inc.
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND...